More so, the ectopic expression of AIM was shown to significantly enhance the anticancer effect of Pembrolizumab and elicited an increased CD8+ T-cell count in AIMhiPSAloPDL1+ PCa cases that were respondent to Pembrolizumab treatment. Here, CD8A is linked to posterior cortical atrophy.